0000950170-23-066386.txt : 20231128 0000950170-23-066386.hdr.sgml : 20231128 20231128160004 ACCESSION NUMBER: 0000950170-23-066386 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230220 FILED AS OF DATE: 20231128 DATE AS OF CHANGE: 20231128 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Giffin Brett A. CENTRAL INDEX KEY: 0001892921 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36571 FILM NUMBER: 231446259 MAIL ADDRESS: STREET 1: 101 HARTWELL AVE. CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: T2 Biosystems, Inc. CENTRAL INDEX KEY: 0001492674 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 204827488 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 101 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-457-1200 MAIL ADDRESS: STREET 1: 101 HARTWELL AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 4/A 1 ownership.xml 4/A X0508 4/A 2023-02-20 2023-03-09 0001492674 T2 Biosystems, Inc. TTOO 0001892921 Giffin Brett A. 101 HARTWELL AVENUE LEXINGTON MA 02421 false true false false Chief Commercial Officer false Common Stock 2023-02-20 4 M false 1333 A 3586 D Common Stock 2023-02-20 4 S false 537 0.65 D 3049 D Restricted Stock Units 2023-02-20 4 M false 1333 0 D Common Stock 1333 2667 D Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The original Form 4 filed on March 9, 2023 is amended by this Form 4 amendment to correct the amount of securities beneficially owned following the reported transactions. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person adopted by the reporting person on November 10, 2021. On February 20, 2022 the reporting person was granted 4,000 RSU's that vest in three equal annual installments commencing on February 20, 2023. /s/ John Sprague, Attorney-in-fact 2023-11-28